Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 2 Interventional

Study of Suramin in Subjects With Furosemide-Resistant AKI

ClinicalTrials.gov ID: NCT04496596

Public ClinicalTrials.gov record NCT04496596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Double-Blind, Placebo-controlled Study of Suramin in Subjects With Furosemide-Resistant Acute Kidney Injury (AKI): Efficacy in Preventing Dialysis Dependent AKI

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a prospective, double-blind, randomized, placebo-controlled study to assess the effects of suramin as a potential treatment option to prevent subjects with AKI from progressing to Kidney Disease Improving Global Outcomes (KDIGO) Stage III or dialysis dependent AKI.

Study identification

NCT ID
NCT04496596
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Rediscovery Life Sciences
Industry
Enrollment
68 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 12, 2020
Primary completion
Apr 16, 2023
Completion
Dec 21, 2023
Last update posted
May 2, 2023

2020 – 2023

United States locations

U.S. sites
12
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
University of Arkansas Medical Sciences (UAMS) Little Rock Arkansas 72205
California Institute of Renal Research La Mesa California 91942
Ronald Reagan UCLA Medical Center Los Angeles California 900953
Emory University School of Medicine Atlanta Georgia 30303
Emory Johns Creek Hospital Johns Creek Georgia 30097
University of Kentucky Lexington Kentucky 40536
University of Missouri - Dept. of Surgery Columbia Missouri 65212
University of New Mexico Health Science Center Albuquerque New Mexico 87131
New York-Presbyterian Medical Center of Queens Flushing New York 11355
Wake Forest Baptist Medical Center Winston-Salem North Carolina 27157-1009
Southeast Renal Research Institute Chattanooga Tennessee 37404
Baylor Scott and White Research Institute - Dallas Clinical Trials Office Dallas Texas 75246

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04496596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 2, 2023 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04496596 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →